Compare Hewlett Packard Enterprise Co (HPE) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Revvity Inc — how do they compare? Hewlett Packard Enterprise Co trades at $73.46 (market cap $94.25B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Hewlett Packard Enterprise Co is far larger — about 5.6× Revvity Inc's market cap, and Hewlett Packard Enterprise Co pays the higher dividend (0.8%). Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and Revvity Inc for 12 Days on average.
| HPE | RVTY | |
|---|---|---|
Market Cap | $94.25B | $16.98B |
Volume | 16,060,854 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $73.46 | $157.36 |
52-Week Low | $20.01 | $82.26 |
Typical Hold Time | 33 Days | 12 Days |
Enterprise Value | $108.28B | $19.30B |
Dividend Yield | 0.8% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hewlett Packard Enterprise (HPE) trades at $70.99, down 1.56% today but near its 52-week high following strong AI-driven momentum. The stock has gained over 160% year-over-year, supported by recent earnings beats and a $1.2 billion AI infrastructure order from Vultr. Technical indicators show bullish moving averages but overbought RSI levels, while fundamentals reveal robust revenue growth projections to $41.9 billion in 2026 despite margin compression in 2025.
HPE presents a compelling growth story fueled by AI infrastructure demand, with analyst consensus leaning bullish (47.5% Buy ratings) and a $70.35 price target. Key risks include elevated valuation multiples (P/E 36.6) and execution challenges in integrating Juniper Networks, but raised guidance and institutional upgrades signal confidence in near-term upside.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
